News ArticleLloyds Metals and Energy Limited Announces Q2 and Half-Year Unaudited Financial Results and Approves Major Investments and Funding Plans
Board approves 360 MW thermal power project, over 13 lakh employee stock options, Rs. 625 crore subsidiary investment, and up to USD 300 million debt issuance
Lloyds Metals and Energy Limited announced its unaudited standalone and consolidated financial results for the quarter and half year ended 30th September 2026. The Board also approved grants of over 13 lakh employee stock options, plans for a 360 MW thermal power plant in Maharashtra, investment up to Rs. 625 crore in a subsidiary, and raising up to USD 300 million through debt issuance.
Lloyds Metals and Energy Limited
General / Other
Lloyds Metals and Energy Limited released its unaudited standalone and consolidated financial results for the quarter and half year ending 30th September 2026, alongside approvals for key strategic projects including a new thermal power plant, significant employee stock option grants, subsidiary capital infusion, and plans for substantial debt raising.
The Board of Directors approved the unaudited financial results, which were reviewed by the audit committee and externally verified through a limited review.
The company granted 62,000 options under its 2017 ESOP plan and 1,308,571 options under the 2024 ESOP scheme.
A major capital expenditure was approved for a 360 MW (2×180 MW) thermal power plant at Konsari, Maharashtra, aimed at supporting internal power needs.
The Board also approved investment up to Rs. 625 crore in its subsidiary, Thriveni Earthmovers and Infra Private Limited, via rights or further issue of capital.
Further, the company received approval to raise up to USD 300 million through issuance of foreign currency-denominated notes and/or INR non-convertible debentures in multiple tranches, subject to regulatory approvals.
Highlights
- Unaudited financial results approved for Q2 and H1 FY 2026-27 with limited review completed.
- 62,000 stock options approved under ESOP 2017 and over 13 lakh under ESOP 2024.
- 360 MW thermal power plant project approved at Konsari, Maharashtra.
- Investment of up to Rs. 625 crore sanctioned for subsidiary Thriveni Earthmovers and Infra Pvt Ltd.
- Authorized to raise up to USD 300 million via debt securities issuance, pending regulatory approval.
Key Data Snapshot
What happened
- The Board approved the unaudited standalone and consolidated financial results for Q2 and half year ended 30th September 2026.
- A limited review of these financial results was completed by independent auditors.
- Grant of a total of 13,70,571 employee stock options under two schemes was sanctioned.
Key details
- Approval of a 360 MW thermal power plant at Konsari, Maharashtra to meet company’s internal power needs.
- Enabling approval to invest up to 30% stake in renewable energy projects to procure 168 MW power for captive consumption.
- Approval for up to Rs. 625 crore investment in subsidiary Thriveni Earthmovers and Infra Pvt Ltd through rights or further equity issuance.
- Authorization to raise funds aggregating up to USD 300 million via issuance of foreign currency notes and/or INR non-convertible debentures in multiple tranches, subject to approvals.
Regulatory and governance context
- Financial results comply with SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.
- Limited review was conducted by Todarwal Todarwal LLP, Chartered Accountants.
- Disclosure requirements under Regulation 30 and 52 of SEBI Listing Regulations followed.
- Use of issue proceeds for Non-Convertible Debentures declared with nil deviation for the quarter ended 30th September 2026.
Highlights
- Unaudited financial results approved for Q2 and H1 FY 2026-27 with limited review completed.
- 62,000 stock options approved under ESOP 2017 and over 13 lakh under ESOP 2024.
- 360 MW thermal power plant project approved at Konsari, Maharashtra.
- Investment of up to Rs. 625 crore sanctioned for subsidiary Thriveni Earthmovers and Infra Pvt Ltd.
- Authorized to raise up to USD 300 million via debt securities issuance, pending regulatory approval.
Disclosures
- SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
- Indian Accounting Standard 34 (Ind AS 34)
- SEBI circular SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November, 2024
More News on General / Other
View allLatest corporate announcements and market updates in General / Other.
Biocon Limited Reports Q2 FY2027 Profit of Rs. 917 Million and Announces New CTO Appointment
Biocon Limited disclosed its unaudited standalone financial results for the quarter and half year ending September 30, 2026, with a quarterly profit of Rs. 917 million. The board also approved the resignation of CTO Dr. Mandar Shrikant Ghatnekar effective December 31, 2026, and the appointment of Mr. Mukesh Rathi as CTO starting January 1, 2027.
Read Full Story
Biocon Reports Q2 FY27 Total Income of Rs 4,423 Crore With Biopharma Revenue Up 5% and $400 Million Pertuzumab Deal
Biocon Limited announced consolidated total income of Rs 4,423 crore for the second quarter of fiscal year 2027, with biopharma revenues increasing by 5% year-on-year to Rs 3,583 crore. The company's EBITDA was reported at Rs 865 crore and net profit at Rs 41 crore. A significant highlight includes securing a 10-year biosimilar Pertuzumab PDP partnership in Brazil valued at about USD 400 million.
Read Full Story
Zydus Lifesciences Posts Rs. 79,096 Million Revenue in Q2 FY27 with Net Profit at Rs. 9,255 Million
Zydus Lifesciences Limited reported strong revenue growth of 29% year-on-year in Q2 FY27 at Rs. 79,096 million, driven by its branded pharma businesses in India, North America, and international markets. However, net profit declined 27% to Rs. 9,255 million, and EBITDA dropped 6% to Rs. 18,945 million, reflecting cost and margin pressures.
Read Full Story
